Neurodegenerative Disease and the NLRP3 Inflammasome.

Holbrook, Jonathan A; Jarosz-Griffiths, Heledd H; Caseley, Emily; Lara-Reyna, Samuel; Poulter, James A; Williams-Gray, Caroline H; Peckham, Daniel; McDermott, Michael F

Holbrook, Jonathan A; Jarosz-Griffiths, Heledd H; Caseley, Emily; Lara-Reyna, Samuel; Poulter, James A; Williams-Gray, Caroline H; Peckham, Daniel; McDermott, Michael F.

Afiliação

Holbrook JA; Department of Clinical Neurosciences, John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, United Kingdom.
Jarosz-Griffiths HH; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom.
Caseley E; Leeds Institute of Medical Research at St. James's University Hospital, Leeds, United Kingdom.
Lara-Reyna S; Leeds Cystic Fibrosis Trust Strategic Research Centre, University of Leeds, Leeds, United Kingdom.
Poulter JA; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom.
Williams-Gray CH; Leeds Institute of Medical Research at St. James's University Hospital, Leeds, United Kingdom.
Peckham D; Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.
McDermott MF; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom.

Front Pharmacol ; 12: 643254, 2021.

Article em En | MEDLINE | ID: mdl-33776778

Palavras-chave

Alzheimer's disease; NLRP3 inflammasome; Parkinson's disease; inflammation; neurodegenerative disease; neuroinflammation

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google